GLP-1 Drugs: How Obesity Pills Are Reshaping a USD 285.20 Billion Market
Executive summary. GLP-1 receptor agonists began as diabetes treatments and have become the most commercially important class of medicines in a generation. Drugs such as semaglutide and tirzepatide help patients control blood sugar and lose significant weight, and demand has outstripped supply for much of the past three years. The next phase is defined by pills, new indications, wider insurance coverage and falling prices. Strategic Revenue Insights estimates the global GLP-1 receptor agonist market at USD 75.00 billion in 2025, reaching USD 157.53 billion by 2030 and USD 285.20 billion by 2035. Oral formulations, expanding indications, easing supply constraints and broader payer coverage are driving it. This article sets out five lessons from the drug makers, payers and care providers moving first, with takeaways for strategy, product, operations, channels and revenue.
The structure of the market shows where growth is concentrating. Strategic Revenue Insights' GLP-1 Receptor Agonist Market research finds that semaglutide is the largest drug with a 30.00 percent share in 2025, that next-generation and oral incretins are the fastest growing drug type, that weekly injections lead by route while oral drugs grow fastest, and that type 2 diabetes is the largest indication while obesity and weight management grows fastest. The research names payer coverage decisions and regulatory hurdles as restraints, and lists Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Amgen, Sanofi, AstraZeneca, Pfizer, Zealand Pharma, Structure Therapeutics and Viking Therapeutics among the key companies.
The shift to pills is already under way. The US Food and Drug Administration approved an oral version of Wegovy, a once-daily semaglutide pill for weight management, in December 2025, and approved Eli Lilly's orforglipron, a small-molecule pill sold as Foundayo, on 1 April 2026 after a 50-day review, according to FDA approvals reported by the Associated Press.
Why the GLP-1 Market Is Entering a New Phase
Three structural forces are converging.
Pills widen access. Injections deter many patients and require cold-chain logistics. SRI's research estimates that oral incretin formulations add 5.0 percentage points to the market's growth rate over the medium term, the largest single driver.
Indications are expanding. GLP-1 drugs are being studied and approved for heart, kidney, liver and sleep-related conditions linked to obesity. SRI's research estimates that expanding approved indications add 4.0 percentage points to growth.
Supply is catching up while prices fall. SRI's research names the resolution of supply constraints as a short-term driver and payer coverage decisions as the main restraint. Lower list prices, discount programmes and generics in some countries are widening access while changing the revenue per patient.
These forces explain SRI's forecast of strong growth to 2035, with value concentrating in oral and next-generation drugs, obesity treatment, home use and online pharmacies.
Five Lessons From the Companies Moving First
The drug makers and care providers turning these forces into advantage share a recognisable pattern. We have distilled it into five lessons, each followed by a takeaway for a specific leadership function.
Lesson 1: The Next Battle Is the Pill
Semaglutide leads today, but SRI's research identifies next-generation and oral incretins as the fastest growing drug type at a 17.1 percent CAGR and oral drugs as the fastest growing route at 16.8 percent. Pills remove the need for injections and are easier to manufacture and ship at scale, especially small molecules such as orforglipron.
The companies moving first run oral programmes alongside injectables, so they can offer patients a choice and protect their franchise as the market moves.
"The first GLP-1 era was won with weekly injections. The second will be won by whoever makes the pill patients actually stay on."
Takeaway on strategy. Build portfolios that span weekly injections, oral peptides and small-molecule pills, and plan for patients moving between them over time.
Lesson 2: Indications Expand the Market
Type 2 diabetes holds 50 percent of the market in SRI's research, but obesity and weight management is the fastest growing indication at a 16.5 percent CAGR. Each new approved indication, from cardiovascular risk reduction to sleep apnoea and kidney disease, brings new patients and new arguments for payers.
The companies moving first invest in outcome trials that show reduced heart attacks, hospital stays and complications, because these trials change coverage decisions. Combination therapies are an opportunity SRI identifies.
Takeaway on product. Fund outcome trials across obesity-related conditions, develop combination therapies, and use clinical evidence to support coverage negotiations.
Lesson 3: Supply and Price Shape Access
Demand for GLP-1 drugs has repeatedly exceeded manufacturing capacity. SRI's research names the resolution of supply constraints as a short-term driver, and price sensitivity in cost-conscious markets as a threat. At the same time, list prices are falling through discount programmes, cash-pay offers and generic entry in some markets.
The companies moving first expand manufacturing for both injectable pens and pills, offer direct cash-pay prices to reach uninsured patients and plan for price erosion as competition grows. The cost of chronic treatment also links to value-based care software, which helps payers track outcomes.
"In GLP-1 drugs, volume is rising faster than price is falling. Capacity and cost to serve now matter as much as the molecule."
Takeaway on operations. Invest in manufacturing capacity for pens and pills, prepare for lower prices per patient, and offer cash-pay options alongside insured access.
Lesson 4: Treatment Is Moving Home and Online
SRI's research identifies home administration as the fastest growing end use at a 15.6 percent CAGR and online pharmacies as the fastest growing distribution channel at a 16.7 percent CAGR. Telehealth platforms, employer programmes and direct-to-patient pharmacies are becoming major routes to treatment.
Long-term treatment also needs support with nutrition, muscle preservation and monitoring. Integration with digital health solutions is an opportunity SRI names. Glucose sensors described in how over-the-counter CGMs are opening metabolic health and nutrition products described in how the GLP-1 consumer is resetting meal replacement are becoming part of the treatment journey.
Takeaway on channels. Partner with telehealth, online pharmacy and employer programmes, and pair drugs with digital monitoring, nutrition and adherence support.
Lesson 5: Emerging Markets Are the Next Frontier
SRI's research focuses on the global market and names expansion into emerging markets as an opportunity. Large populations with rising obesity and diabetes, lower prices and generic semaglutide in some countries will widen access well beyond today's main markets.
The capabilities that decide who captures this demand are specific:
Oral and next-generation incretin pipelines alongside injectables.
Outcome evidence across obesity-related conditions.
Manufacturing scale and readiness for lower prices.
Home, telehealth and online pharmacy distribution.
Pricing and partnerships for emerging markets.
Companies evaluating these competitive dynamics in greater detail can use SRI's GLP-1 Receptor Agonist Market analysis to assess drug type, route, indication, end use and channel segments and the positioning of the leading drug makers.
Takeaway on market development. Build tiered pricing and local partnerships for emerging markets, prepare for generic competition, and register oral products early in high-growth countries.
Where the Opportunity Is Concentrating
Value is moving toward pills, obesity treatment, home use and online channels.
By drug type, semaglutide is the largest, and next-generation and oral incretins grow fastest.
By route, weekly injections lead and oral drugs grow fastest.
By indication, type 2 diabetes is the largest and obesity grows fastest.
By channel, retail pharmacies lead and online pharmacies grow fastest.
At the Horizon: What to Watch Over the Next Three Years
Payer coverage for obesity. Employer and government coverage decisions will decide how many patients can afford long-term treatment.
Oral uptake. Prescription trends for oral semaglutide and orforglipron will show how quickly patients switch from injections.
Price erosion and generics. Generic semaglutide in some markets and discount programmes will reset revenue per patient.
"The next phase of GLP-1 will be won by the companies that make treatment easy to start, affordable to continue and proven to prevent disease."
The Strategic Revenue Opportunity
For drug makers, the task is to win the shift to pills and new indications while managing price. For manufacturers and suppliers, the opportunity lies in pens, active ingredients and oral production. For payers and employers, the priority is coverage tied to outcomes. For investors, the signal is oral uptake, outcome data and coverage decisions.
Market intelligence turns these questions into decisions. Segment-level sizing shows where drug, route and indication demand is concentrating, competitive analysis shows how drug makers are positioned, and channel analysis shows where patients will access treatment. This is the path from market signals to strategic insight to revenue impact.
Takeaway on revenue. Treat the GLP-1 market as four revenue pools: diabetes treatment sold through insured channels, obesity treatment sold through insured and cash-pay channels, oral and next-generation drugs sold on convenience, and digital and nutrition support services sold alongside therapy. Each needs its own pricing model.
The Next Leg: Preparing for the Journey Ahead
The defining shift in GLP-1 drugs is that they are moving from scarce injections to widely available pills for many conditions. That changes how they are priced, prescribed and delivered. The companies moving first are not the ones with a single blockbuster; they are the ones winning the pill, expanding indications, scaling supply, reaching patients at home and online and preparing for emerging markets.
The next three years will decide which companies lead the long-term treatment of obesity and metabolic disease. Decision-makers should invest in oral pipelines, outcome trials and direct-to-patient channels and track coverage, oral uptake and price erosion. Companies evaluating growth opportunities in this market can use Strategic Revenue Insights' GLP-1 Receptor Agonist Market report to assess market size, competitive dynamics, regional opportunities and strategic growth priorities.
Sources: Strategic Revenue Insights, GLP-1 Receptor Agonist Market report (2026); US FDA approvals of oral Wegovy (December 2025) and orforglipron (April 2026), as reported by the Associated Press.
Frequently Asked Questions
How big is the GLP-1 receptor agonist market?
Strategic Revenue Insights estimates the global GLP-1 receptor agonist market at USD 75.00 billion in 2025, reaching USD 157.53 billion by 2030 and USD 285.20 billion by 2035. Semaglutide is the largest drug, and obesity is the fastest growing indication.
What is driving growth in GLP-1 drugs?
Oral incretin formulations, expanding approved indications, the resolution of supply constraints and increased employer and payer coverage are the main drivers of GLP-1 market growth, according to Strategic Revenue Insights. Payer coverage decisions and regulatory hurdles are the main restraints.
Which GLP-1 segments are growing fastest?
According to Strategic Revenue Insights, next-generation and oral incretins are the fastest growing drug type, oral drugs the fastest growing route, obesity and weight management the fastest growing indication, home administration the fastest growing end use and online pharmacies the fastest growing channel.
Are GLP-1 weight loss pills approved?
Yes. The US FDA approved an oral version of Wegovy, a once-daily semaglutide pill for weight management, in December 2025, and approved Eli Lilly's orforglipron, sold as Foundayo, in April 2026. Pills are expected to widen access compared with weekly injections.
About the authors: This article was prepared by the Strategic Revenue Insights research team, which combines market intelligence, competitive analysis and strategic advisory for growth-stage, mid-market and enterprise organisations across the healthcare sector.
Sector analyst: Kamrul Hasan, Research Manager. Our market estimates combine primary research (interviews, surveys and expert panels) with secondary data (industry reports, databases and public disclosures); read more about how Strategic Revenue Insights works. To discuss this market with our analysts, contact our team.
Comments